Davis Simon
Known title: EVP, CHROCIK: 0001609398
Davis Simon's purchase track record
Davis Simon has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/10/2022 | BCO | $505K | -4.9% | -1.3% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BCO | ▼ Sell | Tax Withholding | 566 | $37K | 3/1/2023 | View on chart |
| BCO | ▼ Sell | Other | 4,009 | — | 3/1/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 165 | $11K | 2/24/2023 | View on chart |
| BCO | ▼ Sell | Other | 363 | — | 2/24/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 236 | $15K | 2/20/2023 | View on chart |
| BCO | ▲ Buy | Grant | 2,718 | $0 | 2/16/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 1,154 | $73K | 2/16/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 701 | $42K | 12/3/2022 | View on chart |
| BCO | ▲ Buy | Open Market | 5,000 | $298K | 6/10/2022 | View on chart |
| BCO | ▲ Buy | Open Market | 3,500 | $207K | 6/10/2022 | View on chart |
| BCO | ▲ Buy | Grant | 10,412 | $0 | 3/1/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 105 | $7K | 2/24/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 130 | $9K | 2/21/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 141 | $10K | 2/20/2022 | View on chart |
| BCO | ▲ Buy | Grant | 1,531 | $0 | 2/17/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 446 | $31K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.